alvocidib
Small moleculeexperimental
Alvocidib is a flavonoid alkaloid CDK9 kinase inhibitor under clinical development by Tolero Pharmaceuticals for the treatment of acute myeloid leukemia. It has been studied also for the treatment of arthritis and atherosclerotic plaque formation. The target of alvocidib is the positive transcription elongation factor P-TEFb. Treatment of cells with alvocidib leads to inhibition of P-TEFb and the loss of mRNA production. — Wikipedia
Clinical trial activity
64 trials · 27 clinical orgs · 0 marketing orgs
Phase 1
40
Phase 2
31
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 1997 (NCT00003004)
Timeline
Indications
Studied for
- Anemia · Phase 1
- Anemia, Refractory · Phase 1
- Astrocytoma · Phase 1
- Breast Neoplasms · Phase 1/Phase 2
- Breast Neoplasms, Male · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Small Cell · Phase 1
- Endometrial Neoplasms · Phase 2
- Ependymoma · Phase 1
- Esophageal Neoplasms · Phase 2
- Gastrointestinal Stromal Tumors · Phase 1
- Glioma · Phase 1
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 2
- Hodgkin Disease · Phase 1/Phase 2
- Intestinal Neoplasms · Phase 2
- Kidney Neoplasms · Phase 2
- Leukemia · Phase 2
- Leukemia, Eosinophilic, Acute · Phase 2
- Leukemia, Hairy Cell · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia-Lymphoma, Adult T-Cell · Phase 1/Phase 2
- Leukemia, Monocytic, Acute · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 1
- Leukemia, Myelomonocytic, Acute · Phase 2
- Leukemia, Prolymphocytic · Phase 2
- Liver Neoplasms · Phase 2
- Lymphoma · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large-Cell, Anaplastic · Phase 1/Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 1/Phase 2
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1
- Lymphoma, T-Cell · Phase 1/Phase 2
- Lymphomatoid Granulomatosis · Phase 1/Phase 2
- Medulloblastoma · Phase 1
- Melanoma · Phase 2
- Mesothelioma · Phase 1
- Multiple Myeloma · Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Neoplasms · Phase 1
- Neoplasms, Germ Cell and Embryonal · Phase 2
- Neuroblastoma · Phase 1
- Neuroectodermal Tumors · Phase 1
- Osteosarcoma · Phase 1
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 2
- Retinoblastoma · Phase 1
- Rhabdomyosarcoma · Phase 1
- Sarcoma · Phase 2
- Sarcoma, Ewing · Phase 1
- Seminoma · Phase 2
- Sezary Syndrome · Phase 1/Phase 2
- Stomach Neoplasms · Phase 2
- Testicular Neoplasms · Phase 2
- Thrombocytopenia · Phase 1
- Thromboembolism · Phase 2
- Waldenstrom Macroglobulinemia · Phase 1/Phase 2
- Wilms Tumor · Phase 1
Mechanism of action
- Cyclin-dependent kinase 1INHIBITOR
CDK1 inhibitor
- Cyclin-dependent kinase 4INHIBITOR
CDK4 inhibitor
- Cyclin-dependent kinase 6INHIBITOR
CDK6 inhibitor
- Cyclin-dependent kinase 9INHIBITOR
CDK9 inhibitor
- Cyclin-dependent kinase 2INHIBITOR
CDK2 inhibitor
- Cyclin-dependent kinase 7INHIBITOR
CDK7 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1- Mol. weight
- 401.85 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL428690 ↗
- WikipediaAlvocidib ↗
- ChEMBLCHEMBL2105698 ↗
Also known as
- alvocidib
- alvocidib
- alvocidib
- alvocidib
- alvocidib
- alvocidib freebase
- alvocidib freebase
- alvocidib hcl
- alvocidib hcl
- alvocidib hydrochloride
- alvocidib hydrochloride
- alvocidib hydrochloride
- (-)cis-5,7-dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4h-1-benzopyran-4-one
- flavopiridol
- flavopiridol
- flavopiridol
- flavopiridol
- flavopiridol
- flavopiridol hcl
- hl-275
- hl-275
- hmr 1275
- hmr-1275
- hmr-1275
- l 868275
- l-868275
- l-868275
- l-868275
- l-86-8275
- l-86-8275
- l86-8275
- mdl-107826a
- mdl-107826a
- nsc-649890
- nsc-649890
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04493099 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2020 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT03969420 | Phase 2 | Sep 30, 2019 | Tolero Pharmaceuticals |
| NCT03593915 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2018 | Tolero Pharmaceuticals |
| NCT03441555 | Phase 1 | May 30, 2018 | AbbVie, Tolero Pharmaceuticals |
| NCT03563560 | Phase 1 | May 15, 2018 | Sumitomo Dainippon |
| NCT03298984 | Phase 1 | Sep 25, 2017 | Tolero Pharmaceuticals |
| NCT02520011 | Phase 2 | Mar 14, 2016 | Tolero Pharmaceuticals |
| NCT01349972 | Phase 2 | Apr 1, 2011 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT01076556 | Phase 1 | Apr 1, 2010 | National Cancer Institute (NCI), Ohio State University |
| NCT00991952 | Phase 2 | Sep 1, 2009 | Cornell University, National Cancer Institute (NCI) |
| NCT00957905 | Phase 2 | Jun 1, 2009 | Cornell University, National Cancer Institute (NCI) |
| NCT00795002 | Phase 2 | Nov 1, 2008 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT00634244 | Phase 2 | Oct 1, 2008 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
| NCT00735930 | Phase 1 | Aug 1, 2008 | National Cancer Institute (NCI), Ohio State University |
| NCT00470197 | Phase 1 | Apr 1, 2007 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT00464633 | Phase 2 | Mar 1, 2007 | Sanofi |
| NCT00445341 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2007 | National Cancer Institute (NCI) |
| NCT00407966 | Phase 2 | Oct 1, 2006 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT00377104 | Phase 1 | Sep 1, 2006 | National Cancer Institute (NCI), Ohio State University |
| NCT00324480 | Phase 1 | Mar 1, 2006 | Cornell University, National Cancer Institute (NCI) |
Showing 20 of 64 trials
Page 1 / 4
Organizations
Research & Development (27)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 53 | 43 | 2 | 1997 |
| Cornell University | Academic/Hospital | 14 | 5 | 2 | 1997 |
| Ohio State University | Academic/Hospital | 9 | 0 | 2 | 2003 |
| Johns Hopkins University | Academic/Hospital | 5 | 0 | 2 | 2001 |
| Tolero Pharmaceuticals | For profit | 5 | 4 | 2 | 2016 |
| Harvard University | Academic/Hospital | 4 | 0 | 1 | 2001 |
| Mayo Clinic | Academic/Hospital | 4 | 1 | 2 | 1998 |
| Canadian Cancer Trials Group | Academic/Hospital | 3 | 3 | 1 | 2000 |
| Virginia Commonwealth University | Academic/Hospital | 2 | 1 | 1 | 2003 |
| AbbVie | For profit | 1 | 1 | 1 | 2018 |
| British Columbia Cancer Agency | Academic/Hospital | 1 | 0 | 1 | 2000 |
| Cancer and Leukemia Group B (CALGB) | Academic/Hospital | 1 | 0 | 1 | 1999 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 2001 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Gynecologic Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2001 |
| McGill University | Academic/Hospital | 1 | 0 | 1 | 2000 |
| Northwestern University | Academic/Hospital | 1 | 0 | 1 | 2001 |
| Sanofi | For profit | 1 | 1 | 1 | 2007 |
| Southwest Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2001 |
| Sumitomo Dainippon | For profit | 1 | 1 | 1 | 2018 |
27 organizations
Page 1 / 2